Cargando…

Persistence, Dosing, and Other Treatment Patterns Among Crohn’s Disease Patients Initiating Biologics in United States

BACKGROUND: This study examined biologic persistence, dosing, and other treatment patterns among Crohn’s disease (CD) patients that initiated adalimumab (ADA), certolizumab pegol (CZP), infliximab (IFX), ustekinumab (UST), and vedolizumab (VDZ). METHODS: This descriptive study pooled data from IBM M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teeple, Amanda, Sah, Janvi, Mallampati, Rajesh, Adams, Christopher, Waters, Dexter, Muser, Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802353/ https://www.ncbi.nlm.nih.gov/pubmed/36777272 http://dx.doi.org/10.1093/crocol/otab076

Ejemplares similares

Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn’s Disease Initiated on Biologic or Conventional Agents
por: Pilon, Dominic, et al.
Publicado: (2022)

Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn’s Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States
por: Obando, Camilo, et al.
Publicado: (2020)

Work-Related Productivity Loss and Associated Indirect Costs in Patients With Crohn’s Disease or Ulcerative Colitis in the United States
por: Ding, Zhijie, et al.
Publicado: (2022)

Access to biologicals in Crohn’s disease in ten European countries
por: Péntek, Márta, et al.
Publicado: (2017)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA
por: Pilon, Dominic, et al.
Publicado: (2022)

Insurance Type Influences Access to Biologics and Healthcare Utilization in Pediatric Crohn’s Disease
por: Quiros, Jose Antonio, et al.
Publicado: (2021)

Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn’s Disease Patients with Prescription Claims for Ustekinumab in the USA
por: Ding, Zhijie, et al.
Publicado: (2021)

Extraintestinal Manifestations and Other Comorbidities in Ulcerative Colitis and Crohn Disease: A Danish Nationwide Registry Study 2003–2016
por: Vadstrup, Kasper, et al.
Publicado: (2020)

Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed
por: Nagano, Katsumasa, et al.
Publicado: (2023)

Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study
por: Dotti, Adriana Zanoni, et al.
Publicado: (2023)

The Effect of Early vs Delayed Initiation of Adalimumab on Remission Rates in Patients With Crohn’s Disease With Poor Prognostic Factors: The MODIFY Study
por: Mantzaris, Gerassimos J, et al.
Publicado: (2021)

Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn’s Disease Receiving Biologics: A Retrospective Cohort Study
por: Hunter, Theresa, et al.
Publicado: (2022)

All ileo-cecal ulcers are not Crohn’s: Changing perspectives of symptomatic ileocecal ulcers
por: Toshniwal, Jay, et al.
Publicado: (2017)

Magnesium Links Starvation-Mediated Antibiotic Persistence to ATP
por: Xu, Tao, et al.
Publicado: (2020)

Real-World Persistency for Inflammatory Bowel Disease Biologics Using Patient Registry Data
por: Goss Sawhney, Tia, et al.
Publicado: (2023)

Family history and disease outcomes in patients with Crohn’s disease: A comparison between China and the United States
por: Wang, Pei-Qi, et al.
Publicado: (2016)

Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn’s Disease: A Retrospective Claims Database Analysis
por: Ungaro, Ryan C, et al.
Publicado: (2022)

Pretreatment Vitamin D Concentrations Do Not Predict Therapeutic Outcome to Anti-TNF Therapies in Biologic-Naïve Patients With Active Luminal Crohn’s Disease
por: Chanchlani, Neil, et al.
Publicado: (2023)

Sterilization by Adaptive Immunity of a Conditionally Persistent Mutant of Mycobacterium tuberculosis
por: Vilchèze, Catherine, et al.
Publicado: (2021)

Fungal dysbiosis predicts the diagnosis of pediatric Crohn’s disease
por: El Mouzan, Mohammad I, et al.
Publicado: (2018)

A Novel Capsule Endoscopic Score for Crohn’s Disease
por: Omori, Teppei, et al.
Publicado: (2020)

The Impact of Confounders on Symptom–Endoscopic Discordances in Crohn’s Disease
por: Rajan, Anjana, et al.
Publicado: (2023)

Dose Escalation of Biologics in Biologic-Naïve Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study
por: Ghosh, Sabyasachi, et al.
Publicado: (2023)

Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
por: Ramos, Guilherme Piovezani, et al.
Publicado: (2021)

To Make or Take: Bacterial Lipid Homeostasis during Infection
por: Adams, Felise G., et al.
Publicado: (2021)

Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease
por: Llano, Ernesto M, et al.
Publicado: (2021)

Persistence and In Vivo Evolution of Vaginal Bacterial Strains over a Multiyear Time Period
por: France, Michael, et al.
Publicado: (2022)

Thiopurines are negatively associated with anthropometric parameters in pediatric Crohn’s disease
por: Gupta, Neera, et al.
Publicado: (2018)

Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease
por: Sollelis, Elisa, et al.
Publicado: (2019)

Physical Activity in Adults With Crohn’s Disease: A Scoping Review
por: Neal, Whitney N, et al.
Publicado: (2022)

Zika Virus Is Not Uniquely Stable at Physiological Temperatures Compared to Other Flaviviruses
por: Goo, Leslie, et al.
Publicado: (2016)

Temporal trends in the misdiagnosis rates between Crohn’s disease and intestinal tuberculosis
por: Seo, Hyungil, et al.
Publicado: (2017)

Fecal MicroRNAs Show Promise as Noninvasive Crohn’s Disease Biomarkers
por: Wohnhaas, Christian T, et al.
Publicado: (2020)

When Is a Microbial Culture “Pure”? Persistent Cryptic Contaminant Escapes Detection Even with Deep Genome Sequencing
por: Shrestha, Pravin Malla, et al.
Publicado: (2013)

Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis
por: Mahlich, Joerg, et al.
Publicado: (2021)

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients
por: Foster, Alice Jane, et al.
Publicado: (2019)

Simple pain measures reveal psycho-social pathology in patients with Crohn’s disease
por: Odes, Shmuel, et al.
Publicado: (2017)

Intestinal dysbiosis in pediatric Crohn's disease patients with IL10RA mutations
por: Xue, Ai-Juan, et al.
Publicado: (2020)

Comparison of cytokine and phosphoprotein profiles in idiopathic and Crohn’s disease-related perianal fistula
por: Haddow, James B, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9dk4khriph5viuvnpavb3em1s4